Table 4.

Recurrence-free survival and distant metastasis-free survival rates at 18 months.

	18-Month RFS Rates (N = 200)	18-Month DMFS Rates (N = 200)
Age
<70 years	59.0 (50.3–69.3)	72.2 (63.8–81.7)
≥70 years	60.6 (48.3–76.0)	64.7 (52.5–79.9)
Gender
Female	59.9 (48.8–73.6)	70.7 (60.1–83.1)
Male	59.8 (50.7–70.5)	69.6 (60.5–80.1)
BRAF status
BRAF negative	59.5 (49.4–71.7)	74.0 (64.5–84.9)
BRAF positive	53.4 (42.4–67.2)	61.1 (50.0–74.6)
AJCC stage (8th edition)
Stage IIIA	76.6 (55.8–100)	82.0 (65.2–100)
Stage IIIB	66.7 (53.9–82.6)	77.2 (64.8–91.9)
Stage IIIC	53.0 (43.8–64.2)	64.4 (55.1–75.2)
Stage IIID *	66.7 (37.9–100)	83.3 (58.3–100)

Recurrence-free survival (RFS) and distant metastasis-free survival (DMSF) at 18 months. N: number of patients included in the analysis; AJCC: American Joint Committee on Cancer; BRAF: BRAF mutation status. * Estimates are uncertain due to the small number of patients (n = 7).